GlobeNewswire·Oct 14, 2025, 8:45 AM ET

Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Immix Biopharma will host institutional investor meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA, from November 10-12, 2025.
Management will participate in a Fireside Chat on Tuesday, November 11, 2025, at 12:30pm Eastern Time.
Investors may request one-on-one meetings by contacting their Guggenheim representative, with conference replays to be posted on the Immix website.
The company's lead candidate is NXC-201, a sterically-optimized BCMA-targeted CAR-T therapy featuring a "digital filter" to prevent non-specific activation.
NXC-201 is being evaluated in the registrational multi-center NEXICART-2 study (NCT06097832) for relapsed/refractory AL Amyloidosis.
Interim results from NEXICART-2 met the primary endpoint, as presented at ASCO 2025.
NXC-201 holds Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA, plus Orphan Drug Designation (ODD) from both the FDA \& the EMA.
The press release includes forward-looking statements regarding clinical trial results, business plans, & regulatory progress, noting risks such as trial delays, capital constraints, \& the lack of FDA pre-market approval for any current product.